Capital International Investors’s Royalty Pharma RPRX Stock Holding History

Capital International Investors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.98B	Buy	35,273,770 +268,034	+0.8%	+$14M	0.41%	57
2026 Q1	$1.68B	Buy	35,005,736 +3,901,427	+13%	+$171M	0.39%	61
2025 Q4	$1.2B	Buy	31,104,309 +3,891,615	+14%	+$148M	0.19%	102
2025 Q3	$960M	Buy	27,212,694 +5,332,074	+24%	+$193M	0.16%	112
2025 Q2	$788M	Buy	+21,880,620	New	+$725M	0.14%	132
2023 Q2	–	Sell	-3,831,349	Closed	-$138M	–	446
2023 Q1	$138M	Buy	3,831,349 +189	+0%	+$7.01K	0.04%	262
2022 Q4	$151M	Sell	3,831,160 -1,167,182	-23%	-$48.7M	0.04%	260
2022 Q3	$201M	Buy	4,998,342 +3,735	+0.1%	+$160K	0.06%	239
2022 Q2	$210M	Buy	4,994,607 +1,017	+0%	+$41.7K	0.06%	242
2022 Q1	$195M	Buy	4,993,590 +4,798	+0.1%	+$188K	0.04%	256
2021 Q4	$199M	Buy	4,988,792 +1,325	+0%	+$51.5K	0.04%	269
2021 Q3	$180M	Sell	4,987,467 -11,955,241	-71%	-$465M	0.04%	259
2021 Q2	$694M	Buy	16,942,708 +493,607	+3%	+$21M	0.16%	140
2021 Q1	$718M	Sell	16,449,101 -2,252	-0%	-$107K	0.18%	128
2020 Q4	$823M	Buy	16,451,353 +6,077,310	+59%	+$258M	0.22%	118
2020 Q3	$436M	Buy	10,374,043 +2,236,988	+27%	+$96M	0.13%	147
2020 Q2	$395M	Buy	+8,137,055	New	+$403M	0.13%	143

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital International Investors's RPRX Position: Q2 2026 in Review

Capital International Investors increased its Royalty Pharma (RPRX) stake by 0.77% in Q2 2026, buying an estimated $14M and bringing the position to 35,273,770 shares worth $1.98B. The position accounts for 0.41% of the portfolio, ranked #57.

Capital International Investors first reported a position in RPRX in Q2 2020 and has held it in 17 quarters since. 498 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Capital International Investors held 35,273,770 shares of Royalty Pharma worth $1.98B as of Q2 2026.
Capital International Investors bought 268,034 Royalty Pharma shares in Q2 2026, an estimated $14M.
Royalty Pharma made up 0.41% of Capital International Investors's portfolio in Q2 2026, its #57 holding.
Capital International Investors first reported a position in Royalty Pharma in Q2 2020 and has held it in 17 quarters since.
498 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.